ESMO: Pfizer’s Ibrance flop in early breast cancer shouldn’t hurt metastatic sales, exec says
ESMO: Pfizer’s Ibrance flop in early breast cancer shouldn’t hurt metastatic sales, exec says Pfizer talked up Ibrance’s potential in early breast cancer for years before getting the bad news this May: The Pallas study, examining the drug in stage 2 and stage 3 patients with the HR-positive, HER2-negative form of the disease, was a […]
Read More